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Risk factors for renal allograft loss in patients with systemic lupus
erythematosus. Controversy exists regarding the risk factors for renal
allograft loss in patients with systemic lupus erythematosus (SLE). This
study is a retrospective evaluation of each of these independent risk
factors in 80 renal transplants for ESRD secondary to SLE done at our
institution between 1971 and 1994. Our entire non-diabetic cohort of 1,966
renal transplants is used as a comparison group. Our results showed
equivalent graft survival rates between lupus patients and the cohort at 1,
5 and 10 years (P = 0.56). However, an analysis of cyclosporine-era
cadaver grafts revealed that the lupus group had poorer 5-year graft
survival than the cohort (41% vs. 71%, P = 0.02). Evaluation of
cyclosporine-era lupus graft survival showed significantly improved out-
come in living-related lupus recipients over cadaver grafts at five years
(89% vs. 41%, P = 0.003). The majority of grafts lost in the lupus cadaver
recipients were due to chronic rejection. Rejection was increased in lupus
recipients: 69% of lupus patients experienced rejection in the first year
compared to 58% of controls (P = 0.01). Stratified for age, sex, race and
cyclosporine use, this difference remained significant (P = 0.003, relative
risk 1.7). Nephrectomy, splenectomy and 3 to 6 months of pretransplant
dialysis did not improve graft survival. A dialysis duration of greater than
25 months predicted worse graft survival (P = 0.01). Among lupus
patients, PRA did not correlate with graft outcome (P = 0.5), and
HLA-identical cadaver grafts had improved outcomes compared to ca-
daver grafts. We conclude that acute and chronic rejection are the major
risk factors for graft loss in lupus patients. The superior outcome of
living-related over cadaver grafts in lupus patients suggests an increased
role for living-related grafts. Pretransplant dialysis, nephrectomy and
splenectomy are not indicated.
End-stage renal disease is a significant cause of morbidity and
mortality in patients with systemic lupus erythematosus. Lupus
nephritis accounts for 1 to 2% of renal transplants per year in the
United States. Prior to 1975, lupus was considered a contraindi-
cation to transplantation because of the presumed high likelihood
of recurrent disease. However, in 1975, the Renal Transplant
Registry published results of 60 transplants in 56 patients with
lupus, showing 60% patient and 55% graft survival with no
recurrences at two-year follow-up [1]. These numbers were corn-
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parable to overall graft survival at that time. Since then, trans-
plantation has become an accepted treatment for ESRD in lupus,
with transplanted patient survival equivalent to dialysis-treated
patient survival [2].
Reports from many institutions since the publication of the
Transplant Registry [2—19] have shown graft survival for lupus
patients ranging from 48 to 95% at one year. Studies that have
addressed the variability of these results offer several factors as
possible explanations for the broad range of outcomes: duration
of dialysis prior to transplantation, PRA at time of transplant,
previous nephrectomy and/or splenectomy, number of transfu-
sions prior to transplant, degree of HLA matching, and incidence
of recurrent disease.
Studies that have included matched controls have also had
variable results, some showing a poorer graft survival in lupus 14,
8, 121, and others showing equivalent survival compared to a
control population [2, 5, 11, 13, 16]. Proposed explanations for
these differences have included increased incidence of rejection,
sepsis, and thrombosis in lupus patients. These controlled studies
have also evaluated causes of graft failure and causes of death in
lupus versus control patients.
To identi' and assess risk factors for allograft loss in patients
with end-stage renal disease (ESRD) secondary to lupus, we
conducted a retrospective study of all patients with lupus as a
cause of ESRD transplanted at the University of Wisconsin
Hospital between 1971 and 1994. We compared incidences of
acute and chronic rejection and causes of graft loss and patient
death (including sepsis and thrombosis) in our lupus patients to
our cohort of non-diabetic transplant patients. Within the lupus
group, we evaluated the effects of pre-transpiant dialysis, nephrec-
tomy and splenectomy, PRA, and HLA matching, recurrent
disease and the success of second transplants.
Methods
Patients
We researched the transplantation database for all patients
with ESRD secondary to systemic lupus erythematosus having
undergone renal transplantation at University of Wisconsin Hos-
pital. We identified 69 patients with 80 transplants performed
between 1971 and 1994. Eighteen of these patients had been the
subject of an earlier study [9].
The entire cohort of 1,966 non-diabetic, non-lupus renal trans-
plant patients from the University of Wisconsin Hospital was used
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Lupus Control P value
Mean age years 31 39 <0.001
Sex %female 79 39 <0.001
Race percentage of patients 0.07
White 86 91
Black 13 7
Hispanic 1 2
Transplant number 1.0
First 69 1664
Second 10 255
Third 1 39
Fourth 0 7
Fifth 0 1
Donor source (1st tx. only)
Cadaver 30(44%) 1113 (66%)
Living-related 35 (50%) 493 (30%)
Living-unrelated 4 (6%) 58 (4%)
Total numbers of transplants 80 1966
as the control group. Causes of ESRD in that group included
glomerulonephritis (33%), polycystic kidney disease (12%), and
hypertension (10%). Characteristics of lupus and control patients
were collected. The lupus patients were significantly younger than
the control population (mean age 31 years vs. 39 years; Table 1).
The lupus group had a higher percentage of females (79% vs.
39%). There was a higher percentage of primary transplants in the
lupus group and a higher percentage of living-related grafts.
Immunosuppression prior to 1983 consisted of azathioprine and
prednisone. Since 1983, quadruple therapy with Minnesota anti-
lymphocyte globulin (MALG) and long-term triple maintenance
therapy with azathioprine 1 to 2 mg/kg/day, prednisone 0.1
mg/kg/day and cyclosporine 4 to 6 mg/kg/day have been used.
Living-related recipients have received similar maintenance im-
munosuppression without MALG since 1986.
Data collection
The following information on the lupus patients was obtained
from the database: age, sex, race, date of transplant, episodes of
acute rejection, chronic rejection, duration of dialysis prior to
transplant, post-transplant episodes of sepsis and thrombosis
resulting in graft failure or death, PRA, previous nephrectomy or
splenectomy, degree of HLA match, date and cause of graft
failure, date and cause of patient death, episodes of recurrent
disease, and graft survival of second transplants. Information
obtained for the control patients included: age, sex, race, trans-
plant number, etiology of renal failure, rejection episodes in first
year post-transplant, episodes of sepsis and thrombosis post-
transplant resulting in death or graft failure, and date and cause of
graft failure and patient death.
Statistical analysis
Patient and graft survival estimates were produced with the
Kaplan-Meier product limit estimator. Survival estimates were
compared with the log rank test. Discrete count data were
analyzed with Fisher's exact test (two-tailed). Continuous mea-
surement data were analyzed with Kruskal-Wallis nonparametric
analysis of variance. All analyses were performed with SAS
statistical software [20].
Results are for primary grafts only with two exceptions: the data
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on etiology of graft failure and etiology of patient death include all
transplants.
Results
Overall graft survival rates for lupus patients were 82, 64 and
46% at 1, 5, and 10 years, respectively, which was equivalent to
control graft survivals of 81, 68 and 55% (P = 0.56; Fig. 1). When
results were stratified by age, no overall graft survival difference
was detected between the two groups (P = 0.23). Overall one-year
graft survival for lupus patients in the cyclosporine era was 89%,
considerably improved over the pre-cyclosporine era when one-
year graft survival was 68%. Cyclosporine-era lupus patients had
one- and five-year cadaver graft survival of 91% and 41%, versus
95% and 89% for living related grafts (Fig. 2). Cyclosporine-era
cohort patients had one- and five-year graft survivals of 86% and
71% for cadaver grafts and 95% and 80% for living related grafts.
Table 1. Characteristics of lupus and control patients
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Fig. 1. Comparison of overall primaty graft survival in 69 lupus patients (E)
versus 1663 non-diabetic cohort patients (. No statistical difference was
seen in overall graft survival (P 0.563). (In Figs. I through 3, numbers in
parenthesis refer to number of patients remaining at each data point.)
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Fig. 2. Comparison of cyclosporine-era lupus graft survival for 23 cadaver
grafts (s,) versus 21 living-related grafts ) shows superior outcome fbr the
living-related grafts (P = 0.003).
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The main difference in outcome in the lupus patients appeared to
be five-year graft survival for the 23 cyclosporine-treated cadaver
recipients, whose outcome was significantly worse than that of the
comparable cohort group (41% vs. 71%; P = 0.02; Fig. 3).
Patient survival in the lupus group did not differ from controls:
survival in the lupus group was 97, 91, and 86% compared to 95,
89, and 81% in controls at 1, 5, and 10 years, respectively (P =
0.27; age-stratified P = 0.67). In the cyclosporine era, lupus
recipients of living-related grafts had patient survival equivalent to
cadaver recipients (P = 0.10). The lupus subgroup with the best
survival rate was the cyclosporine-era patients who received
living-related grafts. Their one- and five-year survival rates were
100%. Eight deaths occurred in the lupus group, four due to
cardiac causes, one to peritonitis, two to sepsis and one unknown.
No significant differences in the distribution of causes of death
were seen between the two groups (P = 0.84).
Risk factors for graft failure were evaluated including acute and
chronic rejection, duration of pre-transplant dialysis, episodes of
sepsis and thrombosis, PRA, prior splenectomy and nephrectomy,
HLA, and recurrent disease. Factors that differed significantly
between the lupus and control groups were incidence of acute
rejection and graft loss due to chronic rejection. Lupus patients
showed a greater incidence of acute rejection in the first year
post-transplant compared to controls (69% vs. 56%, P = 0.01).
Cyclosporine-era patients, controlled for age, sex, and race, also
showed a higher incidence of rejection in the lupus group (P =
0.003). The relative risk for rejection in the cyclosporine-treated
lupus patients was 1.7.
Thirty-one grafts were lost in the lupus group and 761 in the
control group (Table 2). Acute and chronic rejection accounted
for the majority of grafts lost in both groups. The percentage of
grafts lost from chronic rejection was significantly higher in the
lupus group: 15 of the 31 grafts lost in the lupus group (48%),
compared to 221 of the 761 grafts lost in the cohort group (29%;
P = 0.027). All other causes of graft failure were equivalent in
both groups.
The subset of lupus patients with the worst prognosis (cadaver
recipients in the cyclosporine era) had significantly poorer graft
survival than their control cohort (P = 0.02). There were a total of
Lupus Controls
Acute rejection 9 (29%) 225 (30%)
Chronic rejection 15 (48%) 221 (29%)
Death with functioning graft 2 (6%) 161 (21%)
Recurrent disease 1(3%) 28 (4%)
Thrombosis 2 (6%) 15 (2%)
Renal pelvic leak 1(3%) 1 (<1%)
Other 1(3%) 110 (14%)
Total 31 761
Discussion
This study is the largest single-center series published on results
of renal transplantation in patients with ESRD secondary to lupus
nephritis. We report the results of 80 renal transplants in 69
patients with lupus at the University of Wisconsin Hospital
compared to our entire cohort of non-diabetic transplant recipi-
ents. Our one-year overall lupus graft survival rate of 82%
compares favorably with results from previous series of cadaver
and living related grafts [1—19]. Table 3 shows these series, with
one-year graft survival ranging from 48% to 87%. The best
subgroup one-year graft survival in our lupus patients was 95%,
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Fig. 3. Comparison of cyclosporine-era cadaver graft survival in
patients () versus 739 non-diabetic cohort patients ).
(5) (4) (4)
I I 23 patients in this subset who were compared with 739 controls.
4 5 6 Etiologies of graft loss in these patients indicated that chronic
rejection accounted for this difference: 77% of lupus cadaver graft
loss versus 23% of cohort graft loss (P = 0.00009).
23 lupus Increased dialysis duration was one factor found to correlate
negatively with graft survival. The relationship between dialysis
duration prior to transplant and graft survival was studied for the
lupus patients only. A longer duration of dialysis prior to trans-
plant was shown to worsen graft survival. More than 25 weeks on
dialysis prior to transplant placed patients at a higher risk for graft
failure (P = 0.01).
Four factors were not significant in graft survival in lupus
patients in this study: sepsis, thrombosis, PRA, nephrectomy, and
splenectomy. The incidence of sepsis as a cause of patient death
or graft failure did not differ between the lupus and control
groups. Renal artery thrombosis caused 2 of 31 graft failures in
the lupus patients and 17 of 761 in controls (P = 0.14). Nephrec-
tomy and splenectomy prior to transplant in patients with lupus
provided no advantage in graft survival, although these small
numbers allowed for only limited analysis. (Eight of 69 patients
had undergone splenectomy prior to transplant, 6 of 69 patients
had undergone bilateral nephrectomy.) Neither PRA at time of
transplant nor peak PRA affected graft survival for lupus patients
in the cyclosporine era (P = 0.48 for PRA at transplant, 0.98 peak
PRA).
Five HLA-identical transplants were done in the lupus group.
One-year survival for these patients was 100%. Graft survival
among lupus patients improved with the degree of HLA matching
when HLA-A, -B, and -DR were evaluated independently. Two
patients (3%) had recurrent lupus nephritis. One of these patients
suffered graft loss at 22 months; the other had recurrent disease
diagnosed 13 years ago but remains alive with a functioning graft.
Ten patients in the lupus group underwent a second transplant.
One-year graft survival for second transplants was 90%, not
significantly different from primary graft survival (P = 0.81).
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Table 3. Selected comparative studies of graft survival in SLE patients receiving kidney transplants
Year Author Controls
NTx!
Npts
Graft survival
(% at 1, 5, 10 years)
Control group
graft survival
(% at 1, 5 years) Immunosuppressiona
1975 Renal Transplant Registry [1] N 60/56 55/—/—' —I— A+P
1983 Mejia [91 N 20/18 59/—!— —I— A+P
1985 National Transplant Registry [4] N 16/15 84/—!— —I— A+P,C+P
1987 Roth [3] Y 142/142 67/—!— 80/— —
1988 Bumgardner [5] Y 33/32 80/70/70 no SD A+P, C+P, A+P+C
1989 Zara [6] N 46/38 74/45/_C
35/l7/'
—I— A+P,C+P
1990 Rivera [7] N 8/8 87/—!— —/— A+P
1990 Nyberg [8] Y 38/31 48/—!— 85!— A+P,C+P, A+P+C
1990 Cheigh [2] Y 18/21 72/60/45 no SD A+P,A+P+C
1991 Goss [10] N 16/14 62/—!— —I— A+P,A+P+C
1991 Krishnan [11] Y 138/138 68/—!— no SD —
1991 Cattran [12] Y 11/11 63/53/_C 84/81
1991 Nossent [14] Y 23/18 61/51/36 no SD A+P,A+P+C
1992 Hariharan [13] N 28/28 68/54!— /— A+P,C+P
1992
1992
Contreras-Rodriguez [15]
Sumrani [16]
N
Y
16/16
43/40
78/52/52
100/94/_f
75/67/_g
—I--
no SD
A+P,C+P
A+C+P
1993 Sokunbi [17] N 6/6 50/—!— —I— A+C+P
1993 Bitker [18] N 11/10 80/—!— —I— A+P,A+C+P
1995 El-Shahay [19] N 64/64 69/61/— —/— A+P,A+C+P
a A, azathioprine; P, prednisone; C, cyclosporineh 2 year results
C yclosporine erad Pre-cyclosporine era
Values are for 6 and 18 months
Living-related donor
g Cadaver donor
for living-related cyclosporine-era grafts. The most significant
finding of this study is the difference in five-year graft survival seen
between cyclosporine-era lupus cadaver grafts and controls (41%
vs. 71%, P = 0.001). Two previous studies have examined these
subgroups and showed no significant difference in graft survival
[Ii, 16]. Cyclosporine-era lupus cadaver grafts also had worse
five-year graft survival than comparable living-related grafts (41%
vs. 89%, P = 0.003). This finding is in agreement with some
studies [8, 9], but others have shown lupus cadaver outcome to be
equivalent to living-related grafts [13, 19]. Our findings point
towards the importance of immunosuppression in this group
(cyclosporine-era lupus cadaver recipients), and a beneficial effect
of living-related grafts in patients with lupus ESRD. Based on our
results, lupus patients should be encouraged to consider a living-
related transplant over a cadaver transplant because of the
improved graft survival. The excellent patient survival and lack of
lupus disease symptoms on chronic dialysis [2, 21—23] may make
dialysis a preferable treatment for patients who do not have a
living-related donor.
Our overall lupus patient survival rates of 97, 91, and 86% at 1,
5, and 10 years are equivalent to those of our cohort, and similar
to rates previously reported by Bumgardner in a large series from
Minnesota [5]. Again, our best outcome was seen in cyclosporine-
era living-related recipients, who had a five-year patient survival
rate of 100%. Patient deaths in the lupus group were due to sepsis
and cardiac causes; no cause of death was found to be more
prevalent than any in the cohort.
Risk factors for graft loss in lupus patients that were found to be
significant in our study were acute and chronic rejection and
pre-transplant dialysis. Acute rejection occurred in 69% of the
lupus patients in the first year, compared to 56% of the cohort.
The majority of previous studies have also shown increased risk of
rejection in lupus patients compared to controls [9, 16, 24, 25],
with values ranging from 40 to 56% of grafts in the first year. The
exception is Bumgardner's group who showed no difference [51.
Chronic rejection was also increased in the lupus group in our
series, most likely as a consequence of increased acute rejection.
This suggests that aggressive immunosuppression is important in
this group. Pretranspiant lupus activity as measured by ANA titers
and other autoantibodies was not evaluated due to lack of
complete records. Other studies have shown no clear effect of
pretransplant serology on graft outcome [3, 10, 13, 26—29].
Longer duration of dialysis worsened graft survival; no duration
of dialysis appeared to provide benefit in graft survival. There has
been extensive debate on this subject, with some studies suggest-
ing optimal timing of three months to two years of dialysis prior to
transplantation [2, 3, 21, 22]. The rationale for this has been to
allow lupus immunologic disease activity to subside under the
immunosuppressive effects of uremia and dialysis. It has also been
suggested that 3 to 28% of patients with ESRD secondary to lupus
have recovered renal function to the point of discontinuing
dialysis [21, 23]. Our study is in agreement with others that
pre-transpiant dialysis provides no benefit to graft survival [5, 6, 8,
10, 14, 19]. The reasons for worsened graft survival with increased
duration of dialysis were not evaluated since the aim of our study
was to determine whether a period of pretranspiant dialysis was
protective. Lupus patients dialyzed for longer periods were more
likely to have received a cadaver graft than a living-related graft.
This would most likely account for the difference in graft survival,
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although the numbers were too small to draw statistically signifi-
cant conclusions.
The higher incidence of graft loss in lupus patients has been
attributed to many factors. These include an increased incidence
of sepsis and thrombosis, higher PRA levels in lupus patients,
antigenic stimulus provided by the native kidneys, increased
antibody production by the spleen, degree of HLA match, and
recurrent disease. None of these factors influenced graft survival
in our series. Sepsis has been shown to be the predominant cause
of mortality in lupus patients [5, 7, 19]. Infection accounted for
37% of deaths in the lupus patients in our study, and no episodes
of graft loss. Our study showed no increased risk of sepsis as a
cause of graft loss or death compared with the control group.
Thrombosis was a rare complication both in lupus patients and
controls; two grafts were lost to renal artery thrombosis in the
lupus group. Thrombosis of the renal vein has been reported [30].
Increased thrombotic tendency in lupus patients has been attrib-
uted to higher titers and incidence of anti-cardiolipin antibody
and anti-phospholipid antibody in lupus patients than in non-
lupus dialysis patients and controls [17, 31]. In a review of 13
patients with lupus anticoagulant and renal transplant, 6 of 16
grafts were lost to renal thrombosis [32]. Lupus transplant pa-
tients with anti-cardiolipin antibody have a higher incidence of
thrombosis than those without the antibody [33]. Our data show
no difference in the incidence of thrombosis as a cause of graft
loss or patient death between lupus patients and controls.
Higher PRA has been reported to worsen graft survival;
Cattran and Aprile [12] showed an 8% difference in graft survival
for patients with PRA > 50 compared to those with PRA < 50.
Hariharan et al showed an increased incidence of graft loss in
patients with PRA> 20 [13]. Cattran and Aprile also showed that
73% of lupus patients undergoing transplantation had a PRA>
50 compared to 13% of non-lupus transplants [121. Our study did
not support the findings of these investigators. PRA was not
shown to affect graft survival. Two previous studies also showed
no effect [14, 19].
In the past, nephrectomy was done at the time of transplant in
lupus patients to remove the diseased organ [3], and splenectomy
was done to alter the immunologic status of the patient. In the
report from the Advisory Committee, improved graft survival was
seen in recipients who had had splenectomy at the time of
transplant (60% vs. 50% graft survival at 2 years) [1]. Our data,
which include small numbers of patients who underwent nephrec-
tomy and splenectomy, show no significant effect on graft survival.
Increased degree of HLA matching was found to correlate with
improved graft survival in our series. HLA-identical recipients in
a series by Roth et a! also had excellent graft survival (8 HLA-ID
patients, 1 failed at 38 months from vasculitis) [3]. Bumgardner
and Zara also report good results with HLA-identical grafts [5, 6].
It has been theorized that HLA-identical kidneys are more
susceptible to graft failure as a result of genetic susceptibility to
recurrent lupus [24]. Our results do not support that theory.
Despite the immunologic origin of lupus, recurrence of lupus
nephritis in renal transplants is rare. Disease recurred in two of
our patients and was the cause of graft loss in one. Approximately
21 cases of recurrent lupus nephritis are reported in the literature
[3, 8, 10, 14, 16, 25—29, 34—40]. Roth has proposed multiple
factors to account for this low incidence, including the immuno-
modulatory effects of uremia and pre-transpiant blood transfu-
sions, and immunosuppressive drugs [31. The improvement in
clinical and serologic manifestations of lupus with the onset of
ESRD is well documented [21, 23]. The incidence of recurrent
disease has been estimated at 1 to 3% [39], but a biopsy study by
Nyberg et a! suggested that this rate may be higher [25].
In our series, second transplant survival was equivalent to first
transplant survival. A report by Hariharan et al has suggested that
a second transplant for patients with lupus has a very poor chance
of survival [13]. Of five second transplants, none survived more
than 34 months. Our results with second transplants are more
compatible with those of Nyberg et a!, who showed 86% graft
survival at three years [8].
Summary
Risk factors for graft loss in renal transplant patients with lupus
were found in this study to include increased incidence of acute
rejection, increased chronic rejection, and pre-transpiant dialysis.
Lupus patients were found to have a relative risk of acute
rejection of 1.7 compared to the control group. A significantly
increased risk of chronic rejection was seen in the lupus patients,
most markedly in the cadaver recipients in the cyclosporine era.
These patients had significantly lower graft survival than the
control group, indicating a need for careful attention to immuno-
suppression. These patients also had significantly lower graft
survival than living-related recipients. This would suggest an
increased role for living-related grafts in patients with ESRD
secondary to lupus. No graft survival benefit was seen with any
period of pre-transpiant dialysis; increased length of pre-trans-
plant dialysis was a predictor of reduced graft survival in lupus
patients. Sepsis, thrombosis, PRA, nephrectomy and splenectomy
had no effect on graft survival. HLA matching improved outcome,
the risk of recurrent disease was low, and good results were
obtained in second transplants for lupus.
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